Hematology NewsSequential triple therapy produces high response rates in CLLJune 21, 2017CLLLeukemia, Myelodysplasia, Transplantation
Hematology NewsHitting BTK, PI3K pays off in B-cell malignanciesJune 20, 2017Mantle Cell LymphomaCLLLymphoma & Plasma Cell Disorders
Hematology NewsiFCG achieves high MRD-negative remission in untreated CLLMay 30, 2017CLLLeukemia, Myelodysplasia, Transplantation
Hematology NewsIn good-candidate CLL, don’t wait too long for alloHCTMay 22, 2017CLLLeukemia, Myelodysplasia, Transplantation
Hematology NewsIbrutinib response in CLL/SLL less affected by select risk factorsMay 21, 2017CLLLeukemia, Myelodysplasia, Transplantation
Hematology NewsTargeted drugs transform CLL managementApril 24, 2017CLLLeukemia, Myelodysplasia, Transplantation
Hematology NewsVenetoclax produces durable effects in relapsed/refractory CLLMarch 29, 2017CLLLeukemia, Myelodysplasia, Transplantation
Hematology NewsAdvanced CLL treatment approach depends on comorbidity burdenMarch 27, 2017CLLLeukemia, Myelodysplasia, Transplantation
Hematology NewsCLL boost in PFS came at high cost in side effectsMarch 8, 2017CLLLeukemia, Myelodysplasia, Transplantation
Hematology NewsCAR designers report high B-cell cancer response ratesMarch 2, 2017CLLCellular TherapyLeukemia, Myelodysplasia, TransplantationFollicular Lymphoma
Hematology NewsUblituximab was safe, highly active in rituximab-pretreated B-cell NHL, CLLFebruary 21, 2017CLLLymphoma & Plasma Cell DisordersLeukemia, Myelodysplasia, Transplantation
Hematology NewsIn CLL, specific mutation is key to ibrutinib resistanceFebruary 13, 2017CLLLeukemia, Myelodysplasia, Transplantation
Hematology NewsIn active CLL with deletion 17p, consider trial enrollmentFebruary 9, 2017CLLLeukemia, Myelodysplasia, Transplantation
